Drug Trial Radar · NCT01382719
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Last checked: Nov 19, 2026Latest source record: Dec 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
612
Actual
Start
Jun 2011
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.
Conditions
- Female Sexual Arousal Disorder
- Hypoactive Sexual Desire Disorder
Interventions
bremelanotideDrug
Subjects will administer drug on an as needed basis, prior to anticipated sexual activity. Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen. Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.
Locations
68 sites in 2 countries. Site status is shown where the registry gives one.
Site 56
Birmingham, Alabama
Site 26
Huntsville, Alabama
Site 64
Mobile, Alabama
Site 45
Chandler, Arizona
Site 39
Phoenix, Arizona
Site 25
Tucson, Arizona
Site 78
Hot Springs, Arkansas
Site 16
Jonesboro, Arkansas
Site 52
National City, California
Site 73
Newport Beach, California
Site 80
Sacramento, California
Site 12
San Diego, California
Site 37
Denver, Colorado
Site 40
Lakewood, Colorado
Site 8
Avon, Connecticut
Site 75
Farmington, Connecticut
Site 33
New London, Connecticut
Site 32
Washington D.C., District of Columbia
Site 10
Aventura, Florida
Site 27
Fort Myers, Florida
Site 66
Melbourne, Florida
Site 61
Orlando, Florida
Site 1
West Palm Beach, Florida
Site 82
Atlanta, Georgia
Site 55
Decatur, Georgia
Site 70
Chicago, Illinois
Site 54
Peoria, Illinois
Site 63
South Bend, Indiana
Site 13
Wichita, Kansas
Site 48
Lexington, Kentucky
Site 57
Zachary, Louisiana
Site 9
Baltimore, Maryland
Site 60
Rockville, Maryland
Site 74
St Louis, Missouri
Site 35
Lincoln, Nebraska
Site 72
Las Vegas, Nevada
Site 24
Las Vegas, Nevada
Site 18
New York, New York
Site 38
Purchase, New York
Site 3
Raleigh, North Carolina
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.